PDF is available of LRG Science here.
First-Line Imatinib More Effective Than Widely Believed
Treatment for Resistant GIST – Improved, but Still Very Far to Go
Authored by LRG Data Analyst Jerry Call*
LRG Science endeavors to be a respected source of timely, science-based information built on real world data designed for those whose focus is to increase patient survival from Gastrointestinal Stromal Tumor (GIST) and other cancers.
In this issue, the LRG Real World Evidence team analyzes data from our Patient Registry in order to evaluate the efficacy of imatinib as a first-line treatment in GIST. The findings suggest that imatinib, when prescribed as a first-line treatment in patients with imatinib-sensitive mutational profiles, is more effective than originally reported in previous studies, and emphasizes the importance of mutational testing as a standard of care for all GIST patients.
Commentary is welcome.
We are actively seeking article submissions for 2020. To inquire further or to submit commentary, please email Mary Garland: firstname.lastname@example.org
*Additional authors: Yu Wang, Sara Rothschild, Denisse Montoya, Pete Knox, Mary Garland, Carolyn Tordella, and Norman J. Scherzer of the Life Raft Group